市場調查報告書
商品編碼
1354344
血液檢測市場規模 - 按測試類型、按產品、按方法、按最終用途、2023 - 2032 年全球預測Blood Testing Market Size - By Test Type, By Product, By Method, By End-use, Global Forecast 2023 - 2032 |
由於 COVID-19 大流行期間對全血細胞計數 (CBC) 檢測的需求激增,血液檢測市場規模預計在 2023 年至 2032 年期間複合年成長率為 6.7%。
事實證明,CBC 測試對於確定患者的整體健康狀況和識別可能的感染至關重要,從而導致其在醫療保健中擴大採用血液診斷。隨著COVID-19患者數量的不斷增加,人們越來越擔心週邊血球會發生實質變化,例如淋巴球減少和嗜中性球增多。根據先前披露的資料,儘管勞動力短缺,安大略省的診斷實驗室在 2021 年 12 月每天仍進行約 50,000 次檢測。事實證明,COVID-19 患者對 CBC 檢測的需求不斷增加,有利於行業成長。
整個血液檢測市場根據檢測類型、產品、方法、最終用途和地區進行細分。
就檢測類型而言,預計到2032年,傳染病篩檢領域的血液檢測市場規模將呈現強勁成長。血液檢測對於早期識別和診斷新的傳染病(例如SARS、登革熱、萊姆病)是必要的。 、尼帕病毒腦炎等。除了診斷技術的發展之外,此類傳染病的高盛行率也將推動該細分市場的擴張。例如,2022 年 5 月,Becton, Dickinson, and Company 在美國推出了其創新的全自動傳染病分子診斷平台
就最終用途而言,預計從2023 年到2032 年,病理學領域的血液檢測市場價值將以顯著的複合年成長率成長。各種傳染性和非傳染性疾病的發病率不斷上升,例如癌症、心血管疾病、胃腸道疾病、腎臟疾病和泌尿系統困難導致需要對這些疾病進行有效的診斷和治療。隨著醫療保健系統優先考慮預防保健和個人化醫療,病理實驗室有望處於診斷和篩檢服務的最前線。
從地區來看,歐洲在2022 年佔據了血液檢測市場的相當大佔有率,並將在2032 年之前實現大幅成長。老年人口基數的增加以及糖尿病及其相關併發症的大量流行將提高該地區的血液檢測率。根據歐洲議會在 2022 年世界糖尿病日提出的估計,歐盟有超過 3,200 萬人患有糖尿病。此外,嚴格的醫療保健法規和對預防保健的關注導致診斷服務的採用率更高。血液檢測技術的不斷創新和對研發活動的更大投入也將有助於市場成長。
Blood Testing Market size is poised to depict 6.7% CAGR from 2023-2032 driven by the surging demand for complete blood count (CBC) tests during the COVID-19 pandemic.
CBC tests have proven essential in determining the general health of patients and identifying possible infections, leading to their increased adoption for blood diagnostics in healthcare. With the rising count of COVID-19 patients, the growing concerns of substantial changes in peripheral blood cells, such as lymphopenia and neutrophilia significantly soared. According to previously disclosed data, despite the workforce shortage, diagnostic laboratories in Ontario conducted about 50,000 tests each day in December 2021. This increasing demand for CBC tests among COVID-19 patients proved favorable for the industry growth.
The overall blood testing market is segmented based on test type, product, method, end-use, and region.
With respect to test type, the blood testing market size from the infectious disease screening segment is estimated to depict robust growth through 2032. Blood testing is necessary for the early identification and diagnosis of new infectious illnesses, such as SARS, dengue fever, Lyme disease, Nipah virus encephalitis, and others. The high prevalence of such infectious illnesses, in addition to the developments in diagnostic technology, will drive the segment expansion. For instance, in May 2022, Becton, Dickinson, and Company launched its innovative, fully automated infectious disease molecular diagnostics platform in the U.S.
In terms of end-use, the blood testing market value from the pathology segment is estimated to expand at notable CAGR from 2023 to 2032. The growing incidence of various communicable and non-communicable diseases, such as cancer, cardiovascular disease, gastrointestinal disorders, renal disorders, and urological difficulties have resulted in the need for effective diagnosis and treatment of the diseases. With healthcare systems prioritizing preventive care and personalized medicine, pathology laboratories are expected to be at the forefront of diagnostic and screening services.
Regionally, Europe held sizable share of the blood testing market in 2022 and is set to record substantial growth through 2032. The rising geriatric population base and the substantial prevalence of diabetes along with complications related to it will increase the rate of blood testing regionally. According to estimations presented by the European Parliament on World Diabetes Day 2022, over 32 million individuals in the EU suffer from diabetes. Moreover, the stringent healthcare regulations and the focus on preventive care is leading to the higher adoption of diagnostic services. Increasing innovations in blood testing technologies and the higher commitment to R&D activities will also contribute to the market growth.